Leap Investments’s Precision BioSciences DTIL Stock Holding History

Leap Investments’s Portfolio DTIL Stock Details DTIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-847	Closed	-$153K	–	441
2020 Q1	$153K	Buy	+847	New	+$222K	0.22%	199

Other funds holding DTIL

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Leap Investments's DTIL Position: Q2 2020 in Review

Leap Investments sold out of Precision BioSciences (DTIL) in Q2 2020, closing a stake of 847 shares — an estimated $153K sold.

Leap Investments first reported a position in DTIL in Q1 2020 and held it in 1 quarter. The position peaked at $153K in Q1 2020. 115 funds tracked by Wall St. Rank hold DTIL as of Q2 2020.

Leap Investments reported no remaining Precision BioSciences position as of Q2 2020 after selling out during the quarter.
Leap Investments sold 847 Precision BioSciences shares in Q2 2020, an estimated $153K.
Leap Investments first reported a position in Precision BioSciences in Q1 2020 and held it in 1 quarter.
Leap Investments's Precision BioSciences position peaked at $153K in Q1 2020.
115 funds tracked by Wall St. Rank held Precision BioSciences as of Q2 2020.

Based on Leap Investments's 13F filing for Q2 2020, filed 3 Aug 2020.